Skip to main content

Table 1 Study design and patient baseline characteristics.*

From: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Study Druga Dose Titration Randomised
patients (N)
Treatment
duration
(weeks)
Baseline severity
(24-hour
pain intensity
score) Mean (sd)
Diabetes
type
(% Type 2)
Diabetes
Duration
(years)
Mean (sd)
Diabetes
Duration
(years)
Median
DPNP
Duration
(years)
Mean
Age
(years)
Mean
(sd)
Gender (% male)
Duloxetine             
HMAW Duloxetine 60 mg QD   112 12 6.01
(1.69)
87.7 11.42
(8.20)
9.87 3.81 59.21
(11.61)
69.3
  Duloxetine 60 mg BID 3 days 109   5.85
(1.38)
90.3 10.06
(8.95)
7.49 3.45 60.5
(10.84)
60.2
  Placebo    115   5.73
(1.52)
90.4 11.44
(11.26)
7.52 4.03 60.42
(10.5)
51.3
HMAVa Duloxetine 60 mg QD   114 12 6.12
(1.62)
91.2 9.74
(9.55)
6.35 3.59 59.71
(11.17)
64.9
  Duloxetine 60 mg BID 3 days 112   6.21
(1.54)
92 9.88
(10.01)
6.65 4.38 61.46
(9.94)
54.5
  Placebo    108   5.85
(1.42)
89.8 11.08
(9.09)
9.11 3.53 60.81
(10.57)
63.9
HMAVb Duloxetine 60 mg QD   116 12 5.55
(1.12)
80.2 14.64
(8.92)
14.06 4.52 58.29
(10.88)
41.4
  Duloxetine 60 mg BID 3 days 116   5.65
(1.29)
85.3 13.93
(9.72)
11.35 4.47 58.98
(9.58)
52.6
  Placebo    116   5.47
(1.25)
87.9 12.83
(8.64)
11.32 3.98 59.2
(9.84)
45.7
Pregabalin             
DPN-029 Pregabalin 100 mg TID 1 wk 82 5 6.2
(1.4)
93.8   7   59
(9.2)
59.3
  Pregabalin 200 mg TID 1 wk 82   6.2
(1.5)
92.7   6.5   62
(9.7)
63.4
  Placebo   1 wk 97   6.6
(1.5)
85.6   8   57.8
(11.6)
60.8
DPN-131 Pregabalin 100 mg TID   76 8 6.5 84.2 9.4
(10.3)
6   59.2
(12.3)
55.3
  Placebo    70   6.1 90 9.3
(10.5)
5.5   60.3
(10.3)
57.1
DPN-014 Pregabalin 50 mg TID 2 wks 79 6 6.5 91.1   4   56.3
(9.4)
 
  Pregabalin 200 mg TID 2 wks 82   6.7 97.6   6.5   57.8
(9.5)
 
  Placebo   2 wks 85   6.9 83.5   9   57.1
(10.3)
 
DPN-040 Pregabalin 200 mg TID 2 wks 87 8 6.9 87.2   10.5   62
(9.4)
 
  Amitriptyline 25 mg TID 2 wks 88   6.4 82.8   9   57.8
(12.0)
 
  Placebo   2 wks 81   6.3 87.7   11   60.6
(11.5)
 
DPN-149 Pregabalin 75 mg BID 1 wks 99 12 6.2 86   12   58.5
(12.6)
 
  Pregabalin 150 mg BID 1 wks 99   6.4 84   12.5   57.6
(10.5)
 
  Pregabalin 150/300 mg BID 1 wk 101   6.6 86   11   59.5
(11.4)
 
  Placebo   1 wk 97   6.4 86   11   58.8
(11.8)
 
DPN-155 Pregabalin 600 mg QID 1 wk 96 8 6.67 82.3 13.2 11.4   61.8
(11)
54.5
  Pregabalin Flexible dose
150 – 600 mg
1 wk 105   6.67 84.8 13.8 10.4   62.7
(10.6)
52.5
  Placebo    48   6.55 81.3 13.6 11.5   61.7
(12.6)
56.9
Gabapentin             
Backonja
1998
Gabapentin 1200 mg TID 4 wks 84 8 6.4 75 12
(9.6)
   53
(10.5)
58.3
  Placebo   4 wks 81   6.5 75 11.2
(8.7)
   53
(10.5)
61.7
Simpson
2001
Gabapentin 1200 mg TID 4 wks 30 8 6.4 80 8
(7.4)
   48
(8.2)
60
  Placebo   4 wks 30   6.5 83 9
(7.8)
   52
(9.8)
60
  1. *Note: duloxetine trial arms with dose 20 mg QD and pregabalin trial arms with dose 25 mg TID were excluded from the meta-analysis;
  2. aQD: Once daily; BID: Twice daily; TID: Three times daily.